Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$2.32 USD
-0.07 (-2.93%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADVM 2.32 -0.07(-2.93%)
Will ADVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
Bet on 5 Top-Ranked Stocks With Rising P/E
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Other News for ADVM
Adverum Biotechnologies (ADVM) Price Target Reduced by Mizuho | ADVM Stock News
Adverum Biotechnologies (ADVM) Price Target Reduced by Mizuho | ADVM Stock News
Adverum Biotechnologies price target lowered to $12 from $16 at Mizuho
Adverum Biotechnologies price target lowered by $4 at Mizuho, here's why
Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)